Journal
JOURNAL OF NEURAL TRANSMISSION
Volume 121, Issue 4, Pages 379-383Publisher
SPRINGER WIEN
DOI: 10.1007/s00702-013-1120-z
Keywords
Parkinson's disease; MAO-A; MAO-B inhibitors; Selegiline; Rasagiline
Categories
Ask authors/readers for more resources
Patients with Parkinson's disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available